REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
27/07/2026
Voltar para busca
Dado oficial do USPTO
TOXSTA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
27
Atualização mais recente
27/07/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5
Data de depósito
03/06/2020
Data de registro
27/07/2021
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
27/07/2021
Última transação
27/07/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
5
Tipo de titular
03
Localização do titular
KR
Examinador
MICHELI, ANGELA M
Unidade examinadora
L10
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
JETEMA CO., LTD.
Representantes
Benjamin M. Cantor Cantor Colburn LLP
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical agents affecting sensory organs; pharmaceutical preparations for treating cramps; pharmaceutical preparations for treating muscle; pharmaceutical preparations for treating cerebral palsy; pharmaceutical preparations for treating hyperhidrosis; pharmaceutical agents affecting metabolism; bacteria poisons; Pharmaceutical preparations for treating headache; anaesthetics; pharmaceutical preparations for use in the cosmetic fieldmedicated cosmetics; pharmaceuticals containing botulinum toxin for medical use for use in the treatment of neurological disordersmuscle disordersnerve disordersheadacheswrinklessports injuriesspasmstremors and pain; botulinum toxin for medical use for use in the treatment of neurological disordersmuscle disordersnerve disordersheadacheswrinklessports injuriesspasmstremors and pain; pharmaceutical preparations for the treatment of urogenital organ disorders; Pharmaceutical preparations for urogenital organs; pharmaceutical preparations for plastic surgery; anti-inflammatory and antipyretic preparations; pharmaceutical agents affecting digestive organs; veterinary substances and preparations for house pets for injuries and painpharmaceuticals containing botulinum toxin; Cardiovascular agents for medical purposes; pharmaceutical preparations for treating neurological disorders; pharmaceutical preparations in the nature of botulinum toxinbotulinum toxin-haemagglutin complexbotulinum toxin fragments and other derivatives used to treat neurological diseases; Ophthalmic preparations; allergy medications; Chemical preparations for pharmaceutical purposesfor neurological disordersmuscle disordersnerve disordersheadacheswrinklessports injuriesspasmstremors and pain; Pharmaceutical agents for epidermis; drugs for medical purposespharmaceutical preparations for the treatment of neurological disordersmuscle disordersnerve disordersheadacheswrinklessports injuriesspasmstremors and pain; pharmaceutical preparations for skincare in the nature of botulinum toxinbotulinum toxin-haemagglutin complexbotulinum toxin fragments and other derivatives for medical purposes; pharmaceutical preparations for skin care treatment in the nature of botulinum toxinbotulinum toxin-haemagglutin complexbotulinum toxin fragments and other derivatives for medical purposes; medicines for human purposespharmaceutical preparations for the treatment of neurological disordersmuscle disordersnerve disordersheadacheswrinklessports injuriesspasmstremors and pain; Pharmaceutical preparations for orthopedic purposes; pharmaceutical preparations for treating wrinkles; analgesic preparations; medicines for dental purposes; pharmaceutical preparations for treating pain; pharmaceutical preparation for skin care; medicated preparations for skin treatment; pharmaceutical preparations for respiratory organs; preparations for the treatment of burns; preparations for the treatment of scar
Publicações
Histórico de despachos e eventos da marca no USPTO.
27 publicações encontradas
NREP
NEW REPRESENTATIVE AT IB RECEIVED
06/10/2023
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
01/01/2022
FICS
FINAL DISPOSITION NOTICE SENT TO IB
13/12/2021
FIMP
FINAL DISPOSITION PROCESSED
13/12/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
27/10/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
27/07/2021
GPNX
NOTIFICATION PROCESSED BY IB
11/05/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/05/2021
PUBO
PUBLISHED FOR OPPOSITION
11/05/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
21/04/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
21/04/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
21/04/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/04/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
31/03/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
31/03/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
31/03/2021
NREP
NEW REPRESENTATIVE AT IB RECEIVED
08/01/2021
RFNT
REFUSAL PROCESSED BY IB
19/10/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
01/10/2020
RFRR
REFUSAL PROCESSED BY MPU
01/10/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
11/09/2020
CNRT
NON-FINAL ACTION WRITTEN
10/09/2020
DOCK
ASSIGNED TO EXAMINER
03/09/2020
MAFR
APPLICATION FILING RECEIPT MAILED
11/08/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/08/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
06/08/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace TOXSTA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.